1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9923
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurphy, Ren
dc.contributor.authorGreen, Sen
dc.contributor.authorRitter, Gen
dc.contributor.authorCohen, Len
dc.contributor.authorRyan, Den
dc.contributor.authorWoods, Wen
dc.contributor.authorRubira, Men
dc.contributor.authorCebon, Jonathan Sen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorSjolander, Aen
dc.contributor.authorKypridis, Aen
dc.contributor.authorKalnins, Renate Men
dc.contributor.authorMcNamara, Men
dc.contributor.authorMoloney, M Ben
dc.contributor.authorAckland, Jen
dc.contributor.authorCartwright, Glenn Aen
dc.contributor.authorRood, Jen
dc.contributor.authorDumsday, Gen
dc.contributor.authorHealey, Ken
dc.contributor.authorMaher, Den
dc.contributor.authorMaraskovsky, Eugeneen
dc.contributor.authorChen, Y Ten
dc.contributor.authorHoffman, E Wen
dc.contributor.authorOld, Lloyd Jen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:12:35Z
dc.date.available2015-05-15T23:12:35Z
dc.date.issued2005en
dc.identifier.citationPreparative Biochemistry & Biotechnology; 35(2): 119-34en
dc.identifier.govdoc15881594en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9923en
dc.description.abstractThe cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.en
dc.language.isoenen
dc.subject.otherAntigens, Neoplasm.biosynthesis.genetics.isolation & purification.therapeutic useen
dc.subject.otherAustraliaen
dc.subject.otherCancer Vaccines.biosynthesis.genetics.isolation & purificationen
dc.subject.otherDrug Industry.standardsen
dc.subject.otherGuidelines as Topicen
dc.subject.otherHumansen
dc.subject.otherMembrane Proteins.biosynthesis.genetics.isolation & purification.therapeutic useen
dc.subject.otherProtein Engineering.methods.standardsen
dc.subject.otherQuality Assurance, Health Care.standardsen
dc.subject.otherRecombinant Proteins.biosynthesis.isolation & purificationen
dc.subject.otherReference Standardsen
dc.titleRecombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.en
dc.typeJournal Articleen
dc.identifier.journaltitlePreparative biochemistry & biotechnologyen
dc.identifier.affiliationroger.murphy@ludwig.edu.auen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Australiaen
dc.description.pages119-34en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15881594en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

48
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.